Abstract: A multiplexed lateral flow device includes an impermeable internal reservoir having an opening to receive a sample deposition. A fluid distributor pad is arranged in fluid communication with a lower surface of the internal reservoir. The fluid distributor pad includes a paper based microfluidic element having a pattern of a hydrophobic material to distribute a portion of the sample deposition substantially equally among a plurality of flow paths. Lateral flow assays having a plurality of flow lines are aligned with flow paths of the distributor pad. An impermeable top cover has a first window arranged over the opening of the internal reservoir, and at least a second window arranged over the test results of the lateral flow assays. A housing element houses the reservoir, the distributor pad and lateral flow assays.

Abstract: The present invention relates to a protein of the scFv type in which said protein comprises a first polypeptide chain and a second polypeptide chain joined by a ligand, having the formula as follows: (VH domain)-(ligand)-(VL domain). The present invention further relates to a polynucleotide comprising the nucleotide sequence shown in SEQ ID NO: 1; to a vector comprising the polynucleotide as defined above; to the host cell comprising the vector as previously defined; and the composition comprising the aforementioned protein and a pharmaceutically acceptable excipient. The present invention further relates to a method for treating a disease or condition that results directly or indirectly from ?4?1 integrin activity. The present invention further relates to an in vitro method for prognosing multiple sclerosis. The present invention further relates to the use of the previously defined protein or composition in the manufacture of a drug for the treatment of multiple sclerosis.

Abstract: The drugs available for the treatment of cutaneous leishmaniasis have unsatisfactory efficacy, frequent and serious adverse effects, and require long treatment regimens. Thus, the search for new treatment alternatives for cutaneous leishmaniasis is considered a priority by the World Health Organization. Parenteral administration of pentavalent antimonials for the treatment of all forms of leishmaniasis, including cutaneous leishmaniasis, has several limitations. The therapy is long, requires repeated doses, and adverse reactions are frequent. Topical treatment is an attractive alternative for cutaneous leishmaniasis, offering significant advantages over systemic therapy: fewer adverse effects, ease of administration, and lower costs. The present inventors aimed to provide a fixed-dose topical composition containing at least one antileishmanial compound, providing adequate absorption of the active ingredient.

Abstract: The present invention relates to a protein receptacle capable of receiving several exogenous polyamino acid sequences, concomitantly, for expression in various systems and for different uses. The present invention relates to polynucleotides capable of generating the aforementioned protein receptacle. The present invention also relates to vector and expression cassette comprising the aforementioned polynucleotide. The present invention further relates to the cell comprising the aforementioned expression vector or cassette. The present invention further relates to a method for producing said protein receptacle and for pathogen identification or disease diagnosis in vitro. The present invention further relates to the use of said protein receptacle and kit comprising said protein receptacle for diagnostic purposes or as vaccine compositions.

Abstract: The present invention provides a LAMP assay device that promotes isothermal RNA/DNA amplification applied to pathogen identification, comprising: a LAMP assay chamber (1); an electronics cabinet (4), a power supply means (7); and a top lid (2) for closing the LAMP assay chamber (1), wherein internally the device comprises: a metal cylindrical thermoblock (8) comprising openings (80) for positioning microtubes (81); a control board with central processing (14); a power electronics board (13); at least one heating element (10) in contact with the thermoblock (8) and adapted to heat the thermoblock (8) by induction; a temperature sensor (9) adapted to measure the temperature of the thermoblock (8); a plurality of RGB LEDs (12) positioned below the thermoblock (8) and adapted to excite each microtube positioned in the thermoblock (8); and a camera (11) positioned below the thermoblock (8) and adapted to capture images of each of the microtubes (81) positioned in the thermoblock (8).

Abstract: The present invention relates to a nucleic acid construct, a recombinant multiply-defective influenza virus, that promotes expression of an immunomodulatory protein in a host. This is applicable to the development of vaccines against infectious diseases, particularly those caused by influenza virus and Coronavirus.

Abstract: An immunogenic composition comprising: a) one or more Plasmodium-derived ribosomal or ribosomal associated protein or immunogenic fragment thereof which has a sequence which is at least about 80%, 85%, 90%, 95%, 98%, 99% or 100% identical to a ribosomal or ribosomal associated protein or an immunogenic fragment of a ribosomal or ribosomal associated protein recited in FIG. 1; or a ribosomal or ribosomal associated protein or peptide or immunogenic fragment thereof as recited in FIG. 2 or FIG. 3; and/or b) a polynucleotide encoding one or more protein, peptide or immunogenic fragment of a); wherein the immunogenic composition is for use in eliciting an immune response in a subject to treat or prevent malaria. Also provided are Plasmodium-derived ETRAMPs and/or histones, or immunogenic fragments thereof, for use in eliciting an immune response in a subject, preferably to treat or prevent malaria.

Abstract: The present invention relates to substitute guinea pig rat models for craniotomy training. In this scenario, the present invention provides a rat model for training in medical craniotomy techniques comprising a body (2) with four legs (21) and a tail (22), and a head (1), similar to those of a rat, wherein the body (2) and the head (1) are attachable (3), and wherein the head (1) comprises a rigid skull. (1), similar to those of a rat, wherein the body (2) and the head (1) are attachable (3), and wherein the head (1) comprises a rigid skull.

Abstract: A multiplexed lateral flow assay device includes an impermeable internal reservoir having an opening to receive a sample deposition. A fluid distributor pad is arranged in fluid communication with a lower surface of the internal reservoir and divides a portion of the sample deposition substantially equally among a plurality of flow paths. Lateral flow assays having a plurality of flow lines are aligned with flow paths of the distributor pad. An impermeable paper top cover has a first window arranged over the opening of the internal reservoir, and at least a second window arranged over the test results of the lateral flow assays. A housing element houses the reservoir, the distributor pad and lateral flow assays. The housing element includes an impermeable bottom cover and a spacer element arranged between the top and bottom covers and, provides a gap between the lateral flow assays and the impermeable paper top cover.

Abstract: Despite recent efforts to eradicate malaria worldwide, this parasitic disease is still considered a major public health problem, with a total of 219 million malaria cases and 435,000 deaths in 2017 After a decade of use, however, resistance to CQ has emerged in some locations, including Southeast Asia, South America, and the Western Pacific region, spreading progressively into malaria-endemic areas, including Africa, where increases in malaria mortality have been observed. This has led, in recent years, to the adoption of artemisinin-based combination therapies. Artemisinin-based combination therapies remain effective in most parts of the world, but recent cases of resistance in Southeast Asia call for new approaches and especially new drugs to treat malaria. Thus, the present invention features CQ analogues of Formula (I) that exhibited high activity against CQ-sensitive and CQ-resistant blood parasites and were also active in mice.

Abstract: The present invention relates to chimeric proteins, their uses and production method comprising native protein fractions from Leishmania infantum for the Visceral Leishmaniasis diagnosis. The invention also relates to nucleic acid, expression cassette, expression vector, host cell, visceral leishmaniasis diagnostic kit, visceral leishmaniasis diagnostic kit, visceral leishmaniasis diagnostic method, and vaccine composition.

Abstract: A heterologous expression cassette, DNA construct and vaccine composition for immunization against flavivirus and/or other pathogens. DNA constructs, recombinant viruses and vaccine compositions containing the recombinant viruses were obtained. This invention also concerns and provide an improved expression vector of the live-attenuated yellow fever 17D virus. Modifications in the expression cassette of heterologous proteins in the intergenic E/NS1 region of the yellow fever 17D vaccine virus, were made. The two new functional domains inserted in the expression cassette were (1) a coding sequence for the N-glycosylation motif, located between the NS1 N-terminal motif and the heterologous protein and (2) a sequence which promoted the proteolytic cleavage, or not, of the recombinant protein in such a way as to release it from its C-terminal containing the transmembrane domains and, consequently, from its association with the membrane of the endoplasmatic reticulum—ER.

Abstract: This invention relates to a device that is intended to synchronize electroencephalograms (EEGs), recorded by any digital equipment, to physical events (sensorial, visual or auditory stimuli) and behavioral events (motor response, vocal response), in order to allow EEG signal mediation for the purpose of visualizing Evoked Potentials or Event-Related Potentials, which are important research subjects in the neurosciences and clinical investigations into neurological and psychiatric pathologies. This invention allows any digital EEG device to be transformed into equipment that can record Evoked Potentials. This invention also provides a method for analog synchronization of EEGs with oscillating electric light-related events and motor behaviors.

Abstract: The present invention provides a LAMP assay device comprising a heating chamber (5) adapted to receive a support rail (2) of at least one sample, in which the support rail (2) is inserted into it through a sample insertion opening (1), in addition, the heating chamber (5) comprises: at least one internal heating element (8a, 8b); a circuit of light-emitting elements (6) positioned on a front or rear wall; and a light sensor circuit (7) on a wall opposite the light emitting element circuit (6).

Abstract: The present invention refers to polypeptides with asparaginase activity that have an increased rate of self-processing compared to human wild L-asparaginase (ASRGL1), with mutation in the ASRGL1 glycine rich loop called HGG loop (Histidine 8-Glycine 9-Glycine 10). Polynucleotides that encode the polypeptides of invention are also described here, expression cassettes comprising so-called polynucleotides, expression vectors, host cells, pharmaceutical compositions, uses of the invention polypeptide in the manufacture of a preventive medicine or cancer treatment and methods to produce the polypeptide of invention and to prevent or treat cancer.

Abstract: The present invention provides a real-time PCR method that allows in a single step the simultaneous detection of etiological agents of bacterial meningitis, more specifically, Neisseria meningitidis, Streptococcus pneumoniae and Haemophilus influenzae. For this, primers were used to amplify particular regions of the genomes of said bacteria. The presence of bacteria in a sample is indicated by the presence of amplicon, which is detected by means of detection methods appropriate to the PCR methodology employed.

Abstract: The instant invention relates to a qualitative predictive method, to a method, use and kit applied to the early differential diagnosis of the most prevalent forms of bacterial and viral meningitis, enabling to detect and distinguish the different forms of meningitis. The invention uses a qualitative predictive method based on combined detection and sequential analysis of the presence/absence of at least three out of four specific biomarkers.

Abstract: Disclosed is a new and emerging serotype of Streptococcus pneumoniae designated serotype 6C, and assays and monoclonal antibodies useful in identifying same. Also disclosed is a novel pneumococcal polysaccharide with the repeating unit {?2) glucose 1 (1?3) glucose 2 (1?3) rhamnose (1?3) ribitol (5?phosphate}. This new serotype may be included in pneumococcal vaccines.

Abstract: The present invention relates to a method for inducing an immune response to the dengue virus, on the basis of DNA and 17D chimeric virus vaccines in combined or co-administered immunisation. The scope of the present invention also includes DNA vaccines against the four serotypes of the dengue virus, produced by forming, from each viral serotype of the dengue virus (DENV1-4), various recombinant plasmids that contain the gene that codes for the E protein, or that contain only the sequence that corresponds to the domain III of this protein. The invention also provides a vaccine composition consisting of (a) DNA vaccines against the four serotypes of the dengue virus; (b) chimeric viruses comprising the modified yellow fever vaccination virus 17D; and (c) a pharmaceutically acceptable carrier, all of which are covered by the scope of the invention.

Abstract: Substantially purified salivary Lu. longipalpis polypeptides, and polynucleotides encoding these polypeptides are disclosed. Vectors and host cells including the Lu. longipalpis polynucleotides are also disclosed. In one embodiment, a method is disclosed for inducing an immune response to sand fly saliva. In other embodiments, methods for treating, diagnosing, or preventing Leishmaniasis are disclosed.